Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7-like 1 pseudogene 4 (RPL7L1P4) is a pseudogene derived from the ribosomal protein L7-like 1 (RPL7L1) gene. Pseudogenes are genomic DNA sequences similar to normal genes but non-functional; they generally do not encode functional proteins and usually do not have biological roles or disease associations attributed to active protein-coding genes. Consequently, RPL7L1P4 is not considered a therapeutic target and no known drugs, biomarkers, or safety concerns are associated. The functional ribosomal protein L7-like 1 gene (RPL7L1) itself is sometimes studied in cancer, but the pseudogene variant (RPL7L1P4) lacks evidence of independent function or clinical relevance[5][1][2][3]. Key points: - RPL7L1P4 is a pseudogene, not an active protein-coding gene. - Not recognized as a drug target, biomarker, or disease gene. - Some database records (and commercial suppliers) include this entry for completeness, but it should not be confused with the protein-coding gene RPL7L1[5][1][2][3]. - Therefore, this is an incorrect target for therapeutic or biomarker applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7-like 1 pseudogene 4 (RPL7L1P4).